We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Test Could Accurately Predict Prostate Cancer Recurrence

By LabMedica International staff writers
Posted on 24 Apr 2014
Print article
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).
A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence.

Prostate cancer is the most common form of cancer in American men and approximately 233,000 new cases of prostate cancer will be diagnosed in the USA in 2014 and about 60% diagnoses are among men aged 65 and older. If the cancer has spread outside the prostate, the malignancy often goes undetected and this means the cancer will return in 30% to 50% of patients.

Scientists at the Princess Margaret Cancer Center (Toronto, ON, Canada) analyzed the prostate cancer tissue of 126 men who had undergone image-guided radiotherapy (IGRT), a treatment that focuses solely on the tumor in the prostate area. All men were predicted to have an intermediate risk of their cancer returning and were followed for an average of 7.8 years.

To investigate DNA in the men's tissue samples, the investigators used array comparative genomic hybridization (aCGH). This is a process that assesses a patient's whole genome and spots regions where there are sections of missing, additional or abnormal DNA. Through information gained using this technique, the team created a genetic signature that was able to accurately identify men who were at high or low risk of prostate cancer recurrence.

The scientists then tested this genetic signature on another group of 150 men who had their prostate cancer tumors removed via radical prostatectomy. These patients were also deemed as being at intermediate risk of cancer recurrence. They found that using the genetic signature, they were able to accurately predict which men were at high or low risk of their prostate cancer returning, just as they were in the first group.

The team tested the oxygen content (hypoxia) of tumors from men who had undergone IGRT. They found that the oxygen content of tumors alone was also able to predict the risk of patients' cancer recurrence. However, when they combined the genetic signature with information about the tumor's oxygen content, they developed a test that can predict a man's risk of prostate cancer with close to 80% accuracy. Men with low levels of genetic changes and low oxygen content in their tumors were less to likely to experience recurrence of prostate cancer, with 93% surviving for five years without it returning. Men who had high levels of genetic changes and high hypoxia were at higher risk of recurrence, with only 49% surviving for five years without prostate cancer returning.

Robert G Bristow, MD, FRCPC, PhD, a professor of oncology, said, “The team needs to validate the test over the next two to three years. But if all goes to plan, our findings could lead to a new test for cancer patients that will enable doctors to determine which patients require treatment that is not confined to the prostate region.” The study was presented at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) held April 4-8, 2014 in Vienna (Austria).

Related Links:

Princess Margaret Cancer Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.